| Ulcerative Colitis

Omvoh vs Simponi

Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.
Deep comparison between: Omvoh vs Simponi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsSimponi has a higher rate of injection site reactions vs Omvoh based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Simponi but not Omvoh, including UnitedHealthcare
Sign up to reveal the full AI analysis
Omvoh
Simponi
At A Glance
IV infusion / SC injection
Every 4 weeks
IL-23 antagonist
SC injection
Every 4 weeks
TNF-alpha inhibitor
Indications
  • Ulcerative Colitis
  • Crohn Disease
  • Rheumatoid Arthritis
  • Arthritis, Psoriatic
  • Ankylosing spondylitis
  • Ulcerative Colitis
Dosing
Ulcerative Colitis Induction: 300 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 200 mg SC injection every 4 weeks starting Week 12.
Crohn Disease Induction: 900 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 300 mg SC injection every 4 weeks starting Week 12.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once a month.
Ulcerative Colitis (adults and pediatric patients >=40 kg) 200 mg SC at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks.
Ulcerative Colitis (pediatric patients >=15 kg to <40 kg) 100 mg SC at Week 0, 50 mg at Week 2, then 50 mg every 4 weeks.
Contraindications
  • Previous serious hypersensitivity reaction to mirikizumab-mrkz or any excipient
—
Adverse Reactions
Most common (>=2%) - Ulcerative Colitis Upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, herpes viral infection
Most common (>=5%) - Crohn Disease Upper respiratory tract infections, injection site reactions, headache, arthralgia, elevated liver tests
Serious Intestinal sepsis, listeria sepsis, pneumonia, abscess, cellulitis, sepsis
Most common (>=1%) Upper respiratory tract infection, viral infections, bronchitis, superficial fungal infections, sinusitis, injection site reaction, alanine aminotransferase increased, aspartate aminotransferase increased, hypertension, dizziness, paresthesia, constipation
Serious Serious infections, malignancies, congestive heart failure, demyelinating disorders, hepatitis B reactivation, autoimmunity, hematologic cytopenias, hypersensitivity reactions
Postmarketing Serious systemic hypersensitivity reactions, sarcoidosis, melanoma, Merkel cell carcinoma, interstitial lung disease, skin exfoliation, lichenoid reactions, rash, bullous skin reactions
Pharmacology
Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and suppressing downstream pro-inflammatory cytokine and chemokine release involved in mucosal inflammation.
Golimumab is a human IgG1 monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing its binding to receptors and inhibiting the biological activity of TNF-alpha in inflammatory diseases.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Omvoh
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
View full coverage details ›
Simponi
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Omvoh
  • Covered on 4 commercial plans
  • PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Simponi
  • Covered on 4 commercial plans
  • PA (8/8) · Step Therapy (7/8) · Qty limit (7/8)
View full coverage details ›
Humana
Omvoh
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
View full coverage details ›
Simponi
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Omvoh Savings Program - Covered benefit
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Simponi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
OmvohView full Omvoh profile
SimponiView full Simponi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.